ID Medical voted Best Place to Work in Healthcare Recruitment
Written by Caryn Cooper
ID Medical has claimed its crown for the ‘Best Recruitment Company to Work for’ (£40-100m) in the most exclusive, prestigious and admired awards in the recruitment industry. The Recruitment International Awards 2013 (RI), which were hosted in central London on Thursday 31st October, is the summit of those leading recruitment companies which have made it into RI’s annual Top 250 league.
The merit of this redeemed accolade was formed through why ID Medical is unique, why it is an employer of choice and how it stands head and shoulders above its competitors. ID Medical responded with its winning case, highlighting its vast array of 2013 achievements, its excellent retention rates as well as its employee diversity, engagement level and development programmes.
The UK’s leading multi-discipline healthcare recruiter qualified to enter the Recruitment International Awards following its upward movement in the Recruitment International Top 250, from 89th position to 68th, whilst improving upon its 9th placement to 7th in the sub-category ‘Top 20 healthcare companies.’
Teri Etherington at Recruitment International commented, “There was fierce competition for the Best Recruitment Company to Work for (£40 - £100million) award and it was an extremely difficult category to judge. We were delighted to announce ID Medical as deserved winners.”
A proud Deenu Patel, managing director at ID Medical, who accepted the award, spoke: “Attracting, retaining and promoting top talent within ID Medical is a key priority and I am elated that we have been recognised as the best-in-class employer by Recruitment International.
“I know that we have the best Learning & Development (L&D) training in the industry and the business’s success is somewhat owed to the quality of Continual Professional Development (CPD) and the training our workforce receives.
“Although unemployment figures are rising, ID Medical continues to offer endless career opportunities for young, bright and entrepreneurial individuals, equipping them with the training they need to succeed within the recruitment industry, whilst ensuring the working environment here is dynamic, motivating and overall, a great place to work.”
About the Author
Caryn Cooper is the author of this article
Introducing Dosis - the AI powered dosing platform
Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works.
When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing.
The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced.
What is the Strategic Anemia Advisor?
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease.
SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool.
What else is Dosis working on?
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs.
What are Dosis' strategic goals for the next 2-3 years?
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.
What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.